Página principal > Resultados de la búsqueda: Herrera, Álex F.
  Consejos para la búsqueda
Búsqueda avanzada
Buscar colecciones:
Ordenar por: Mostrar resultados: Formato de visualización:
Depósito Digital de Documentos de la UAB Encontrados 2 registros  La búsqueda tardó 0.01 segundos. 
1.
10 p, 680.7 KB Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma / Ahmed, Sairah (University of Texas) ; Kanakry, Jennifer A. (National Institutes of Health (Bethesda, Estats Units d'Amèrica)) ; Ahn, Kwang Woo (Medical College of Wisconsin) ; Litovich, Carlos Alejandro (Medical College of Wisconsin) ; Abdel-Azim, Hisham (University of Southern California Keck School of Medicine) ; Aljurf, Mahmoud Deeb (King Faisal Specialist Hospital and Research Centre (Aràbia Saudita)) ; Bacher, Vera Ulrike (Inselspital. Bern University Hospital) ; Bejanyan, Nelli (Immunotherapy. Moffitt Cancer Center) ; Cohen, Jonathon B. (Emory University School of Medicine) ; Farooq, Umar (University of Iowa Hospitals and Clinics) ; Fuchs, Ephraim Joseph (The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins) ; Bolaños-Meade, Javier (The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins) ; Ghosh, Nilanjan S. (Levine Cancer Institute. Atrium Health) ; Herrera, Alex F. (City of Hope National Medical Center) ; Hossain, Nasheed (Loyola University Chicago-Stritch School of Medicine) ; Inwards, David (Mayo Clinic) ; Kanate, Abraham Sebastian (West Virginia University) ; Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ; Munshi, Pashna (Georgetown University Hospital) ; Murthy, Hemant S. (University Florida College of Medicine) ; Mussetti, Alberto (Institut Català d'Oncologia-Hospitalet) ; Nieto, Yago (University of Texas) ; Perales, Miguel-Angel (Memorial Sloan Kettering Cancer Center) ; Romee, Rizwan (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Savani, Bipin N. (Vanderbilt University Medical Center) ; Seo, Sachiko (Dokkyo Medical University) ; Wirk, Baldeep Mona (Seattle Cancer Care Alliance) ; Yared, Jean A. (University of Maryland) ; Sureda, Anna (Institut Català d'Oncologia-Hospitalet) ; Fenske, Timothy S. (Medical College of Wisconsin) ; Hamadani, Mehdi (Medical College of Wisconsin) ; Universitat Autònoma de Barcelona
Classic Hodgkin lymphoma (cHL) patients with relapsed or refractory disease may benefit from allogeneic hematopoietic cell transplantation (allo-HCT), but many lack a matched sibling donor (MSD). Herein, we compare outcomes of 2 reduced-intensity conditioning (RIC) HCT platforms in cHL: T cell-replete related donor haploidentical (haplo) HCT with a post-transplant cyclophosphamide (PTCy)-based approach versus an MSD/calcineurin inhibitor (CNI)-based approach. [...]
2019 - 10.1016/j.bbmt.2019.05.025
Biology of blood and marrow transplantation, Vol. 25 Núm. 9 (september 2019) , p. 1859-1868  
Registro completo - Creative Commons
2.
9 p, 1.3 MB Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma / Dickinson, Michael (University of Melbourne. Sir Peter MacCallum Department of Oncology) ; Briones Meijide, Javier (Institut d'Investigació Biomèdica Sant Pau) ; Herrera, Álex F. (Department of Hematology and Hematopoietic Cell Transplantation. City of Hope National Medical Center) ; Gonzalez-Barca, Eva (Institut d'Investigació Biomèdica de Bellvitge) ; Ghosh, Nilanjan (Department of Hematologic Oncology and Blood Disorders. Levine Cancer Institute. Atrium Health) ; Cordoba, Raul (Hospital Universitario Fundación Jiménez Díaz) ; Rutherford, Sarah C. (Meyer Cancer Center. Division of Hematology and Medical Oncology. Weill Department of Medicine. New York-Presbyterian Hospital. Weill Cornell Medicine) ; Bournazou, Eirini (Roche Innovation Center New York. Roche Pharma Research and Early Development) ; Labriola-Tompkins, Emily (Roche Innovation Center New York. Roche Pharma Research and Early Development) ; Franjkovic, Izolda (Roche Innovation Center Munich. Roche Pharma Research and Early Development) ; Chesne, Evelyne (Roche Innovation Center Basel. Roche Pharma Research and Early Development) ; Brouwer-Visser, Jurriaan (Roche Innovation Center New York. Roche Pharma Research and Early Development) ; Lechner, Katharina (Roche Innovation Center Munich. Roche Pharma Research and Early Development) ; Brennan, Barbara (Roche Innovation Center New York. Roche Pharma Research and Early Development) ; Nüesch, Eveline (Roche Innovation Center Basel. Roche Pharma Research and Early Development) ; DeMario, Mark (Roche Innovation Center New York. Roche Pharma Research and Early Development) ; Rüttinger, Dominik (Roche Innovation Center Munich. Roche Pharma Research and Early Development) ; Kornacker, Martin (Roche Innovation Center Basel. Roche Pharma Research and Early Development) ; Hutchings, Martin (Rigshospitalet. Copenhagen University Hospital) ; Universitat Autònoma de Barcelona
Bromodomain and extraterminal (BET) proteins are transcriptional activators for multiple oncogenic processes in diffuse large B-cell lymphoma (DLBCL), including MYC, BCL2, E2F, and toll-like receptor signaling. [...]
2021 - 10.1182/bloodadvances.2021004619
Blood advances, Vol. 5 Núm. 22 (November 2021) , p. 4762-4770  
Registro completo - Creative Commons

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.
Depósito Digital de Documentos de la UAB :: Buscar :: Enviar :: Personalizar :: Ayuda
Powered by Invenio v1.1.6
Mantenido por ddd.bib@uab.cat  :: Metadatos sujetos a:
Colaboramos